Publications - Corcept Therapeutics

PUBLICATIONS

Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.

Relacorilant, A Selective Glucocorticoid Receptor Modulator, In Combination With Nab-Paclitaxel Improves Progression-Free Survival In Patients With Recurrent Platinum-Resistant Ovarian Cancer: A 3-Arm, Randomized, Open-Label, Phase 2 Study

Lorusso et al. • 2021 • European Society for Medical Oncology (ESMO) Congress 2021

Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells

Greenstein et al. • 2021 • Oncotarget . 2021 Jun 22;12(13):1243-1255. doi: 10.18632/oncotarget.27989.

Adrenal tumors provide insight into the role of cortisol in NK cell activity

Greenstein et al. • 2021 • Endocr Relat Cancer . 2021 Jun 29;28(8):583-592. doi: 10.1530/ERC-21-0048.

Suppression of Tumor Immune Activity in Adrenocortical Carcinoma with Excess Glucocorticoid

Greenstein et al. • 2020 • AACR Annual Meeting 2020

Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol.

Greenstein et al. • 2020 • Citation: J Clin Oncol 38: 2020 (suppl; abstract #: 3091)

Relacorilant With Nab-paclitaxel: Safety and Activity in Patients With Pancreatic Ductal Adenocarcinoma and Ovarian Cancer

Munster et al. • 2019 •

1H-pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoidreceptor antagonists with high functional activity.

Clark et al. • 2008 • Bioorg Med Chem Lett. 2008;18(4):1312-7.

Assessment of safety, tolerability, pharmacokinetics, and pharmacological effect of orally administered CORT125134: an adaptive, double-blind, randomized, placebo-controlled phase 1 clinical study.

Hunt et al. • 2017 • Clin Pharmacol Drug Dev. 2017 Oct 2. doi: 10.1002/cpdd.389.

FKBP5 mRNA expression is a biomarker for GR antagonism.

Bali et al. • 2016 • J Clin Endocrinol Metab. 2016;101(11):4305-4312.

Identification of the clinical candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): a selective Glucocorticoid Receptor (GR) antagonist.

Hunt et al. • 2017 • J Med Chem. 2017;60(8):3405-3421.